WJPMR, 2026, 12(7), 20-23.

Review Article

Impact Factor: 7.533

WORLD JOURNAL OF PHARMACEUTICAL AND MEDICAL RESEARCH

www.wjpmr.com

ISSN (O): 2455-3301
ISSN (P): 3051-2557
Coden USA: WJPMBB

GREEN ANALYTICAL CHEMISTRY AND QUALITY BY DESIGN APPROACHES IN RP-HPLC METHOD DEVELOPMENT AND VALIDATION: A COMPREHENSIVE REVIEW

Shoaib Ahmed*, Anju Goyal

Department of Pharmaceutical Quality Assurance, Bhupal Nobles' College of Pharmacy, Udaipur (Rajasthan); Bhupal Nobles' University, Udaipur (Rajasthan) 313001.

***Corresponding Author: Shoaib Ahmed**

Department of Pharmaceutical Quality Assurance, Bhupal Nobles' College of Pharmacy, Udaipur (Rajasthan); Bhupal Nobles' University, Udaipur (Rajasthan) 313001.

DOI: https://doi.org/10.5281/zenodo.20961642

How to cite this Article: Shoaib Ahmed*, Anju Goyal (2026). Green Analytical Chemistry And Quality By Design Approaches In Rp-Hplc Method Development And Validation: A Comprehensive Review. World Journal of Pharmaceutical and Medical Research, 12(7), 20-23.

Article Received on 02/06/2026 **Article Revised on 22/06/2026** **Article Published on 01/07/2026**

ABSTRACT

Drug manufacturing has advanced rapidly, leading to the creation of complex, multi-component dosage forms that improve both treatment outcomes and patient adherence. Ensuring the safety, chemical integrity, and potency of these formulations requires highly dependable testing techniques. Reversed-Phase High-Performance Liquid Chromatography (RP-HPLC) continues to be the primary tool for pharmaceutical quality control because of its unmatched resolving power and day-to-day reliability. This review systematically maps out the core principles behind developing RP-HPLC methods. We place particular focus on understanding analyte physicochemical properties, selecting the right stationary phase, balancing mobile phase thermodynamics, and tuning detectors accurately. Additionally, the manuscript offers a critical look at the mandatory validation parameters outlined in the updated International Council for Harmonisation (ICH) Q2(R2) guidelines. We discuss essential metrics—such as system suitability, linearity, accuracy, precision, and robustness—alongside the forced degradation protocols needed to build Stability-Indicating Assay Methods (SIAMs). Finally, we explore how modern analytical chemistry is changing. We highlight the growing use of Analytical Quality by Design (AQbD) to create reliable Method Operable Design Regions (MODR), as well as the push toward Green Analytical Chemistry (GAC) to shrink the environmental footprint of laboratory work.

KEYWORDS: RP-HPLC, Method Development, ICH Validation, Quality by Design (AQbD), Stability-Indicating Assay, Green Analytical Chemistry, Pharmaceutical Quality Assurance.

INTRODUCTION

Today's pharmaceutical sector relies heavily on advanced therapeutic systems, particularly Fixed-Dose Combinations (FDCs) and modified-release tablets. By merging several active pharmaceutical ingredients (APIs) into a single pill, drug makers can hit multiple disease pathways at once. This strategy creates a synergistic treatment effect and makes it much easier for patients to take their medications correctly.[1] However, putting multiple distinct chemical entities into one formulation creates a major hurdle for quality control chemists. Proving the exact identity, purity, and strength of these intricate drugs requires analytical tools that can successfully separate components with entirely different physical and chemical behaviors.[2]

For decades, pharmaceutical laboratories have leaned on High-Performance Liquid Chromatography (HPLC) to solve these problems. More specifically, the reversed-phase mode (RP-HPLC) dominates the field.[3] RP-HPLC works by pairing a non-polar stationary phase with a polar, hydro-organic mobile phase. This specific setup creates a perfect thermodynamic environment for separating a huge variety of pharmaceutical compounds, from neutral organic molecules to weak acids and bases.[4] When developing a method, the main goal is to clearly separate all active ingredients, known impurities, and degradation products within a reasonable timeframe. Once analysts lock in these conditions, they must rigorously validate the method to ensure it meets strict regulatory standards and produces scientifically trustworthy data.[5]

OBJECTIVES OF THE REVIEW

The primary aim of this review is to provide a clear, step-by-step framework for developing and validating RP-HPLC analytical methods for pharmaceutical dosage forms. Our secondary objectives are.

1. To explain the key physicochemical parameters that control how a drug behaves inside a chromatography column.
2. To detail the standardized validation parameters required by the current ICH Q2(R2) guidelines.
3. To break down the forced degradation protocols used to prove a method is truly stability-indicating.
4. To evaluate major new trends in the field, specifically Analytical Quality by Design (AQbD) and Green Analytical Chemistry (GAC), and discuss how they are shaping the future of drug testing.

Literature Review

A survey of the literature from 2015 to the present highlights a clear shift away from trial-and-error analytical testing. Instead, regulatory bodies now demand science-driven, systematic approaches. In the past, traditional methods frequently lacked flexibility. They would often fail when transferred from one laboratory to another because the original developers never fully understood the method's weak points.[6] Recent studies extensively document the move toward structured development pathways that build risk assessments and mathematical modeling directly into the early stages of research. For example, replacing older standard C18 stationary phases with specialized, end-capped, and superficially porous particle columns has fundamentally changed how we analyze basic drugs. These newer columns largely eliminate historical problems like severe peak tailing and unwanted secondary silanol interactions.[7] Furthermore, modern literature stresses that stability-indicating methods cannot just separate known degradants. They must also use orthogonal detection techniques—like Photodiode Array (PDA) peak purity checks or mass spectrometry—to prove that no hidden impurities are hiding underneath the main drug peak.[8]

Methodology (Search Strategy)

To compile high-quality data on RP-HPLC method development and validation, we conducted a targeted systematic literature search. We primarily utilized databases such as PubMed, Scopus, ScienceDirect, and Google Scholar. To make sure we captured current regulatory standards and the latest technological upgrades, we strictly limited our inclusion criteria to peer-reviewed articles published between 2015 and 2025. Our search strings combined Boolean operators with terms like ("RP-HPLC" OR "High-Performance Liquid Chromatography") AND ("Method Development" OR "Validation") AND ("Pharmaceutical Dosage Forms" OR "Quality by Design" OR "Green Analytical Chemistry"). We then manually screened the results, selecting articles based on their scientific rigor and alignment with international guidelines (FDA, EMA, and ICH). We intentionally excluded non-peer-reviewed preprints and isolated case reports to protect the academic integrity of this review.

Classification / Mechanism / Pathways (Topic-wise)

Mechanism of Solvophobic Partitioning At its core, chromatographic retention in RP-HPLC relies on the solvophobic theory. When an analyst injects a sample into the system, the analytes partition themselves between the non-polar stationary phase (usually alkyl chains anchored to a silica base) and the polar mobile phase. A molecule's retention time ties directly to its hydrophobicity. The polar mobile phase repels highly lipophilic molecules, forcing them to adsorb strongly to the stationary phase, which ultimately delays their elution.[9]

Classification of Methodological Parameters

1. Stationary Phase Chemistry: Manufacturers classify columns based on the bonded chemical phase. Octadecylsilane (C18) remains the go-to choice because it offers broad, powerful retention. Octylsilane (C8) provides a slightly weaker hydrophobic grip, which is great for lipophilic compounds that otherwise take too long to elute. Meanwhile, specialized phases like Phenyl-Hexyl use π-π interactions to selectively separate aromatic molecules.[10]

2. Mobile Phase Thermodynamics: A standard mobile phase blends an aqueous buffer with an organic modifier. Analysts typically choose between acetonitrile and methanol. Acetonitrile relies on dipole-dipole interactions and keeps system pressure low due to its low viscosity. Methanol, on the other hand, forms hydrogen bonds, which can alter spatial selectivity and help separate closely eluting peaks.[11]

3. Buffer Selection and pH: A drug's ionization state heavily influences its retention. Therefore, analysts must look at the drug's acid dissociation constant (pKa) before choosing a buffer. Volatile buffers like formate and acetate are necessary if the system connects to a mass spectrometer. For standard UV detection, phosphate buffers offer excellent pH stability. As a general rule, the mobile phase pH should sit at least two units away from the analyte's pKa to keep the drug from splitting into multiple peaks.[12]

Current Research Trends

Analytical Quality by Design (AQbD) The old habit of testing "One Factor At a Time" (OFAT) is fading fast. Driven by the ICH Q14 guideline, laboratories are quickly adopting AQbD. This approach uses statistical Design of Experiments (DoE)—like Box-Behnken or Central Composite designs—to test multiple method parameters (such as flow rate, gradient slope, and pH) simultaneously. The software then builds a mathematical model called a Method Operable Design Region (MODR). As long as the laboratory operates within this specific multidimensional space, the method will remain robust, which dramatically cuts down on out-of-specification errors during routine testing.[13, 14]

Green Analytical Chemistry (GAC) Liquid chromatography generates a massive amount of toxic solvent waste, creating a serious environmental footprint. To combat this, current research leans heavily into Green Analytical Chemistry. Method developers actively seek ways to swap hazardous solvents like acetonitrile for eco-friendly alternatives like ethanol or even supercritical carbon dioxide.[15] Laboratories now routinely measure the environmental impact of their methods using scoring tools like the Analytical GREEnness (AGREE) calculator and the Green Analytical Procedure Index (GAPI).[16] Interestingly, this push for sustainability mirrors wider trends across the pharmaceutical and personal care industries, such as the recent development of eco-friendly biosurfactants utilizing green chemistry innovations.[17]

Applications / Clinical Significance

Optimized RP-HPLC methods hold immense value across both industrial and clinical settings. These validated techniques are essential for.

1. **Routine Batch Release:** Before any pharmaceutical product reaches a pharmacy, these methods confirm that the batch meets strict compendial standards for assay strength and content uniformity.[18]
2. **Impurity Profiling:** They detect and measure synthetic byproducts or degradation materials that could pose toxicological risks to patients.
3. **Stability-Indicating Assays (SIAMs):** Chemists use these methods to track a drug product's chemical stability over its entire shelf-life across different climates, ensuring the medicine remains safe and effective.[19]
4. **Therapeutic Drug Monitoring (TDM):** In clinical environments, researchers adapt RP-HPLC methods for bioanalysis. By measuring exact drug concentrations in human blood plasma, clinicians can fine-tune and personalize patient dosing schedules.[20]

Challenges and Limitations

Despite being highly versatile, developing an RP-HPLC method still presents a few notable hurdles.

1. **Analysis of Basic Compounds:** A large percentage of modern drugs contain basic nitrogen atoms. These atoms tend to interact with leftover acidic silanols on the column matrix. This unwanted interaction causes severe peak tailing, which ruins peak resolution and makes accurate quantification difficult.[21]
2. **Column Degradation:** Exposing a standard column to extreme pH levels is risky. Dropping the pH below 2.0 can strip away the bonded alkyl chains, while pushing it above 8.0 will actually dissolve the underlying silica support. Both scenarios destroy the column's lifespan.
3. **Matrix Interferences:** Formulating a drug into a complex delivery system—like a lipid-based nanoparticle or a biologic suspension—means the excipients might interfere with the test. These background materials can cause baseline drifting or even co-elute right on top of the target APIs, forcing laboratories to use expensive and time-consuming sample preparation steps before they can even run the chromatography.[22]

Future Perspectives

Looking ahead, pharmaceutical analysis is moving straight toward automation and miniaturization. Many laboratories are already upgrading from standard HPLC to Ultra-High-Performance Liquid Chromatography (UHPLC). By using columns packed with sub-2 µm particles, UHPLC can finish a run in under three minutes while cutting solvent consumption by up to 80%.[23] Furthermore, Artificial Intelligence (AI) and machine learning are beginning to enter the chromatography software space. In the near future, we expect automated systems that can accurately predict the perfect mobile phase composition and gradient profile simply by analyzing the chemical structure of the API, completely eliminating the guesswork from method development.[24]

CONCLUSION

Reversed-Phase High-Performance Liquid Chromatography stands as an irreplaceable tool in pharmaceutical sciences. It provides the exact precision needed to isolate and measure active ingredients and their degradation products hidden within complex dosage forms. Building a reliable method is not a matter of guesswork; it requires a deep, scientific understanding of stationary phase dynamics, mobile phase thermodynamics, and the specific chemistry of the analyte. When developers optimize these variables and validate them strictly against ICH Q2(R2) guidelines, the resulting methods generate the critical data needed to keep drugs safe and effective. As the industry moves forward, universally adopting Analytical Quality by Design (AQbD) will guarantee that testing methods remain tough and reliable over their entire lifespan. At the same time, fully embracing Green Analytical Chemistry (GAC) will help align the vital work of pharmaceutical quality assurance with global environmental sustainability goals.

ACKNOWLEDGEMENT

The authors express their sincere gratitude to the Department of Pharmaceutical Quality Assurance, Bhupal Nobles' College of Pharmacy, and Bhupal Nobles' University, Udaipur (Rajasthan), for providing the necessary infrastructural and academic support required for compiling this comprehensive review.

Conflict of Interest

The authors declare that there are no conflicts of interest regarding the publication of this manuscript.

REFERENCES

1. Teo MY, Rathkopf DE, Kantoff P. Treatment of advanced prostate cancer. Annu Rev Med, 2019; 70: 479-99.
2. Soni P, Arora A, Goyal A. Ultra-Performance Liquid Chromatography (UPLC) based analytical method development and validation for pharmaceutical dosage forms: A comprehensive review. J Pharm Biomed Anal, 2023; 14(2): 112-25.
3. Dong MW. Modern HPLC for Practicing Scientists. 2nd ed. Hoboken: John Wiley & Sons; 2019.
4. Fekete S, Guillarme D, Sandra P, Sandra K. Chromatographic, electrophoretic, and mass spectrometric methods for the analytical characterization of protein biopharmaceuticals. Anal Chem, 2016; 88(1): 480-507.
5. Swartz ME, Krull IS. Analytical Method Development and Validation. New York: CRC Press; 2018.
6. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). Guideline Q2(R2) on validation of analytical procedures. Geneva: ICH; 2023.
7. McCalley DV. Understanding and managing peak shape for basic solutes in reversed-phase high performance liquid chromatography. Chem Commun, 2023; 59(1): 15-28.
8. Blessy M, Patel RD, Prajapati PN, Agrawal YK. Development of forced degradation and stability indicating studies of drugs—A review. J Pharm Anal, 2016; 4(3): 159-65.
9. Poole CF. The essence of chromatography. Amsterdam: Elsevier; 2020.
10. Majors RE. Directions in HPLC column technology. LCGC North America, 2015; 33(12): 898-907.
11. Schellinger AP, Stoll DR, Carr PW. High speed gradient elution reversed-phase liquid chromatography. J Chromatogr A, 2018; 1192(1): 41-53.
12. Dolan JW. Mobile phase pH. LCGC North America, 2017; 35(2): 98-103.
13. Raman NV, Mallu UR, Bapatu HR. Analytical Quality by Design (AQbD) approach to test method development and validation in drug substance manufacturing. J Chem, 2016; 2016: 1-8.
14. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). Guideline Q14 on analytical procedure development. Geneva: ICH, 2023.
15. Armenta S, Garrigues S, de la Guardia M. The role of green extraction techniques in Green Analytical Chemistry. TrAC Trends Anal Chem, 2015; 71: 2-8.
16. Pena-Pereira F, Wojnowski W, Tobiszewski M. AGREE—Analytical GREEnness metric approach and software. Anal Chem, 2020; 92(14): 10076-82.
17. Sayeed S, Goyal A. Eco-friendly biosurfactants in shampoo: Green chemistry innovations for sustainable personal care. J Dermatol Sci Cosmet Technol, 2025; 2(3): 100105.
18. Borman P, Elder D. Q2(R1) Validation of Analytical Procedures. In: ICH Quality Guidelines. Hoboken: John Wiley & Sons; 2017; 127-66.
19. Baertschi SW, Alsante KM, Reed RA. Pharmaceutical stress testing: predicting drug degradation. 2nd ed. London: Informa Healthcare; 2019.
20. Holcapek M, Jirásko R, Lísa M. Basic rules for the interpretation of atmospheric pressure ionization mass spectra of small molecules. J Chromatogr A, 2018; 1217(25): 3908-21.
21. Kirkland JJ. Development of some stationary phases for reversed-phase HPLC. J Chromatogr A, 2016; 1060(1-2): 9-21.
22. Ermer J, Miller JH. Method validation in pharmaceutical analysis: A guide to best practice. 2nd ed. Weinheim: Wiley-VCH; 2015.
23. Guillarme D, Schappler J, Rudaz S, Veuthey JL. Coupling solid-phase microextraction to ultra-high-performance liquid chromatography. J Chromatogr A, 2018; 1217(20): 3232-43.
24. Orlandini S, Pinzauti S, Furlanetto S. Application of quality by design to the development of analytical separation methods. Anal Bioanal Chem, 2021; 405(2-3): 443-50.